O R Shabutdinova, A R Dautov, A A Samkov, A V Kononenko, A F Sargaliev, A R Davletshin, P A Andresova, K R Zarbeeva, D A Torshkhoeva, U A Rakhmonkulov, A A Afanasyev
{"title":"[Semaglutide -根据SUSTAIN, PIONEER, STEP的研究使用时的减肥效果和副作用]。","authors":"O R Shabutdinova, A R Dautov, A A Samkov, A V Kononenko, A F Sargaliev, A R Davletshin, P A Andresova, K R Zarbeeva, D A Torshkhoeva, U A Rakhmonkulov, A A Afanasyev","doi":"10.14341/probl13197","DOIUrl":null,"url":null,"abstract":"<p><p>Overweight and obesity are a worldwide common problem and are diagnosed with a body mass index (BMI) value in the range of 25.0-29.9 kg/m2 and ≥30.0 kg/m2, respectively. Obese patients are at high risk of developing concomitant diseases, such as hypertension, type 2 diabetes mellitus (DM2), hyperlipidemia, stroke and even some types of cancer. In the Russian Federation in 2016, the proportion of overweight people was 62.0%, with obesity - 26.2%. The authors performed an electronic search in the PubMed information database. Two search elements were used: «Semaglutide» and «Obesity». The search included studies published from the date of foundation of the database to August 2022. The search was limited only to the results of clinical trials. The authors obtained 26 results, but only the studies of SUSTAIN, PIONEER (Peptide Innovation for Early Diabetes Treatment) and STEP were considered, since they were original, randomized, controlled clinical trials conducted before the approval of semaglutide for the treatment of DM2 and obesity.</p>","PeriodicalId":20433,"journal":{"name":"Problemy endokrinologii","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350618/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP].\",\"authors\":\"O R Shabutdinova, A R Dautov, A A Samkov, A V Kononenko, A F Sargaliev, A R Davletshin, P A Andresova, K R Zarbeeva, D A Torshkhoeva, U A Rakhmonkulov, A A Afanasyev\",\"doi\":\"10.14341/probl13197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Overweight and obesity are a worldwide common problem and are diagnosed with a body mass index (BMI) value in the range of 25.0-29.9 kg/m2 and ≥30.0 kg/m2, respectively. Obese patients are at high risk of developing concomitant diseases, such as hypertension, type 2 diabetes mellitus (DM2), hyperlipidemia, stroke and even some types of cancer. In the Russian Federation in 2016, the proportion of overweight people was 62.0%, with obesity - 26.2%. The authors performed an electronic search in the PubMed information database. Two search elements were used: «Semaglutide» and «Obesity». The search included studies published from the date of foundation of the database to August 2022. The search was limited only to the results of clinical trials. The authors obtained 26 results, but only the studies of SUSTAIN, PIONEER (Peptide Innovation for Early Diabetes Treatment) and STEP were considered, since they were original, randomized, controlled clinical trials conducted before the approval of semaglutide for the treatment of DM2 and obesity.</p>\",\"PeriodicalId\":20433,\"journal\":{\"name\":\"Problemy endokrinologii\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350618/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Problemy endokrinologii\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14341/probl13197\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Problemy endokrinologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/probl13197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
超重和肥胖是世界范围内的常见问题，诊断为体重指数(BMI)值分别为25.0-29.9 kg/m2和≥30.0 kg/m2。肥胖患者并发疾病的风险很高，如高血压、2型糖尿病(DM2)、高脂血症、中风甚至某些类型的癌症。2016年俄罗斯联邦超重人口比例为62.0%，肥胖人口比例为26.2%。作者在PubMed信息数据库中进行了电子检索。使用了两个搜索元素:«Semaglutide»和«Obesity»。检索包括从数据库建立之日起至2022年8月发表的研究。研究仅限于临床试验的结果。作者获得了26项结果，但仅考虑了SUSTAIN、PIONEER (Peptide Innovation for Early Diabetes Treatment)和STEP的研究，因为它们是在西马鲁肽被批准用于治疗DM2和肥胖之前进行的原始、随机、对照临床试验。
[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP].
Overweight and obesity are a worldwide common problem and are diagnosed with a body mass index (BMI) value in the range of 25.0-29.9 kg/m2 and ≥30.0 kg/m2, respectively. Obese patients are at high risk of developing concomitant diseases, such as hypertension, type 2 diabetes mellitus (DM2), hyperlipidemia, stroke and even some types of cancer. In the Russian Federation in 2016, the proportion of overweight people was 62.0%, with obesity - 26.2%. The authors performed an electronic search in the PubMed information database. Two search elements were used: «Semaglutide» and «Obesity». The search included studies published from the date of foundation of the database to August 2022. The search was limited only to the results of clinical trials. The authors obtained 26 results, but only the studies of SUSTAIN, PIONEER (Peptide Innovation for Early Diabetes Treatment) and STEP were considered, since they were original, randomized, controlled clinical trials conducted before the approval of semaglutide for the treatment of DM2 and obesity.
期刊介绍：
Since 1955 the “Problems of Endocrinology” (or “Problemy Endocrinologii”) Journal publishes timely articles, balancing both clinical and experimental research, case reports, reviews and lectures on pressing problems of endocrinology. The Journal is aimed to the most topical issues of endocrinology: to chemical structure, biosynthesis and metabolism of hormones, the mechanism of their action at cellular and molecular level; pathogenesis and to clinic of the endocrine diseases, new methods of their diagnostics and treatment. The Journal: features original national and foreign research articles, reflecting world endocrinology development; issues thematic editions on specific areas; publishes chronicle of major international congress sessions and workshops on endocrinology, as well as state-of-the-art guidelines; is intended for scientists, endocrinologists diabetologists and specialists of allied trade, general practitioners, family physicians and pediatrics.
![[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP].](https://img.booksci.cn/booksciimg/2023-6/2023110278257812629383873470496.jpg)
![[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP].](https://img.booksci.cn/booksciimg/2023-6/202311027828314967195321915622.jpg)
![[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP].](https://img.booksci.cn/booksciimg/2023-6/202311027828479554549124209176.jpg)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
